A new drug called RNK08954 is being tested for people with non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) that have a specific genetic change called the KRASG12D mutation. In an early-phase clinical trial, 36 patients received the drug and were followed for a median of about 5 months.
Among those with NSCLC, 58.33% had their tumors shrink (an unconfirmed response). For patients with PDAC who received a higher dose (1,000 to 1,200 mg), 33.33% had tumor shrinkage. These results are promising but not yet confirmed, meaning some responses may not last.
No safety details were reported in this summary, so it is too early to know the drug's side effects. The study is very early (Phase Ia) and small, so the findings are not definitive.
What this means for you: If you or a loved one has a KRASG12D mutation cancer, this drug is still experimental. More research is needed to confirm if it works and is safe. Talk to your doctor about clinical trials if you are interested.